AzTrials
AzTrials

HealthyPhase 1NCT04772274

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects

A Phase 1 study testing Ustekinumab in people with Healthy, run by Samsung Bioepis Co., Ltd. at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a randomised, double-blind, three-arm, parallel group, single-dose study to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of SB17 compared to EU sourced Stelara® and US sourced Stelara® in healthy subjects Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
Ustekinumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
201 participants
Where
1 siteFrance
Study dates
4 Feb 2021to 1 Apr 2022
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy male or female, aged 18-55 years (inclusive) on the day of signing the informed consent.
  • Have a body weight between 60.0-90.0 kg (inclusive) and a body mass index (BMI) between 19.0-29.9 kg/m2 (inclusive) at Screening and Day -1.
  • Have 12-lead electrocardiogram (ECG) results without clinically significant abnormal findings confirmed by the Investigator at Screening and Day -1.
  • Have vital sign results without clinically significant abnormal findings confirmed by the Investigator at Screening and Day -1.
  • Have physical examination results without clinically significant abnormal findings confirmed by the Investigator at Screening and Day -1.
  • Female subjects who are not pregnant or nursing at Screening and Day -1, and subjects who are not planning to become pregnant during study period and until 15 weeks after the IP administration.
Show all 12Show fewer
  • Female subjects of non-childbearing potential, defined as one of the following:
  • At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., appropriate age) and follicle-stimulating hormone (FSH) in the range for menopausal female confirmed by blood test according to current local standards at Screening
  • Those with history of hysterectomy or surgical removal of both ovaries. Documentation of surgical procedure performed at least 90 days prior to Screening or documentation of physical examination is required for confirmation of surgical sterilisation OR Female subjects of childbearing potential or male subjects with their (respectively male or childbearing female) partners who agree to use at least two forms of appropriate contraception method (e.g., established use of oral, injected, intravaginal, transdermal, or implanted hormonal contraceptive, placement of an intrauterine device or intrauterine hormone-releasing system, physical barrier [Note: Female condom and male condom should not be used together]) from Screening until 15 weeks after the IP administration. Vasectomy alone will be allowed for male subjects and female subjects of childbearing potential with a sole vasectomised male partner. Vasectomised subjects or partners should be medically confirmed for sterilisation. True abstinence alone will be allowed if this is in line with the preferred and usual lifestyle of the subject, or for subjects who do not have a partner. Contraceptive methods do not apply for subjects whose partner is on the same gender.
  • Willing and able to comply with the scheduled visits, treatment plan, clinical laboratory tests, and other study procedures including lifestyle considerations.
  • Provision of signed and dated written informed consent, which must be obtained prior to any study-related procedures being performed.
  • Have competence in speaking, writing, and comprehending the local language(s) where the study is conducted.

Who cannot join

  • Have a history and/or current presence of clinically significant atopic allergy, hypersensitivity, or allergic reactions (either spontaneous or following drug administration), also including known or suspected clinically relevant drug hypersensitivity to ustekinumab or to any of the excipients.
  • Have a history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological, neurologic (including reversible posterior leukoencephalopathy syndrome), metabolic (including known diabetes mellitus), psychiatric disorder, drug or alcohol abuse, or allergic disease excluding mild asymptomatic seasonal allergies.
  • Have a history of significant respiratory disorder (including asthma, non-infectious pneumonia).
  • Have a history of malignancy (including lymphoma, leukaemia, and skin cancer).
  • Have either active or latent tuberculosis (TB) as indicated by a positive test result for Mycobacterium tuberculosis at Screening or who have a history of TB.
  • Have a history of serious infection (associated with hospitalisation and/or which required IV antibiotics) within 180 days prior to Randomisation.
Show all 37Show fewer
  • Have a history of invasive systemic fungal infections (e.g., histoplasmosis) or other opportunistic infections judged relevant by the Investigator.
  • Have a clinically significant active infection (bacterial, viral, or fungal) within 28 days prior to Randomisation.
  • Have any systemic or local infection, a known risk for developing sepsis and/or a known active inflammatory process at Screening or Day -1.
  • Have previously been exposed to ustekinumab (Stelara® and its biosimilar).
  • Have previously been exposed to a monoclonal antibody or fusion protein within 270 days (other than ustekinumab) prior to Randomisation and/or there is confirmed evidence or clinical suspicion of immunogenicity from previous exposure to a monoclonal antibody or fusion protein.
  • Have previously been exposed to an immunosuppressive agent or biological agent (any other than a monoclonal antibody or fusion protein) within 120 days prior to Randomisation.
  • Have received Bacillus of Calmette and Guerin (BCG) vaccine within 12 months prior to Randomisation or will require BCG vaccine within 12 months after the IP administration.
  • Have received live vaccine(s) (other than the BCG vaccine) within 30 days prior to Randomisation or will require live vaccine(s) within 15 weeks after the IP administration.
  • Have a personal or family history of prolonged QT interval syndrome or Torsade de Pointes, or family history of sudden death.
  • Have any of the following abnormal laboratory test results at Screening or Day -1.
  • Serum C-reactive protein ≥ 1.5 × upper limit of normal (ULN)
  • Serum alanine transaminase (ALT) and/or aspartate transaminase (AST) ≥ 1.5 × upper limit of normal (ULN).
  • Any other laboratory abnormalities assessed as clinically significant by the Investigator
  • Have a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody at Screening.
  • Have a history of immunodeficiency.
  • Have had surgery (including invasive dental treatment or dental surgery) within 90 days prior to Randomisation, and/or plan to have an operation during the study period.
  • Have had a history and/or current presence of an illness within 14 days prior to Randomisation that is classified as clinically significant by the Investigator.
  • Have a history of and/or current Coronavirus Disease-2019 (COVID-19) defined as one of the following:
  • Positive test result for COVID-19 by an antigen test for SARS-CoV-2 at Day -1. (An antigen test for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be performed twice at Day -1. Pharyngeal swab specimen will be collected separately for each test. If any of two tests are positive, the subject will be excluded from the study.)
  • Signs and symptoms consistent with COVID-19 (e.g., fever, dry cough, dyspnea, sore throat, or fatigue) 30 days prior to Randomisation.
  • Have had a positive test result for COVID-19 confirmed by SARS-CoV-2 detection using real-time reverse transcriptase polymerase chain reaction (RT-PCR).
  • Had a severe course of COVID-19 (e.g., extracorporeal membrane oxygenation (ECMO) or mechanically ventilate).
  • Have smoked more than 10 cigarettes, 2 cigars, or 2 pipes per day within 90 days prior to Randomisation.
  • Have regular consumption of alcoholic beverages that exceeds 14 units per week (1 unit = 12 g of pure alcohol).
  • Have a positive urinary drug screening result or alcohol breath test result at Screening or Day -1.
  • Have taken any prescription medicine or over-the-counter medicines (except paracetamol) within 30 days prior to Randomisation that might have an effect on the objectives of the study in the opinion of the Investigator.
  • Have donated > 100 mL blood or plasma within 28 days prior to Randomisation.
  • Have participated in another study with an investigational drug within 60 days prior to Randomisation or are currently participating in or intending to participate in another clinical study of an investigational drug before completion of all scheduled evaluations in this clinical study.
  • Subjects who, in the opinion of the Investigator, are not likely to complete the study for whatever reason.
  • Subject who is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the clinical study.
  • Vulnerable subjects (e.g., persons kept in detention).

Trial locations and contacts

1 site in 1 country.

France1 site

  • Biotrial Rennes

    Rennes

Other trials in France

About this study

Official title: A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Ustekinumab (SB17, EU Sourced Stelara®, and US Sourced Stelara®) in Healthy Subjects

This is a randomised, double-blind, three-arm, parallel group, single-dose study to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of SB17 compared to EU sourced Stelara® and US sourced Stelara® in healthy subjects

Read the detailed description

This study is a randomised, double-blind, three-arm, parallel group, single-dose study. A total of 201 healthy subjects aged 18-55 years will be randomised 1:1:1 to receive a single dose of either SB17, EU sourced Stelara®, or US sourced Stelara®. All investigational products (IPs) will be administered subcutaneously in the abdomen.

Conditions
Healthy
Being tested
Ustekinumab

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • UstekinumabDrug

    45 mg, single-dose

Study groups in NCT04772274
Study groupRoleWhat they receive
SB17ExperimentalSB17 (proposed ustekinumab biosimilar)
Receives: Drug: Ustekinumab
EU StelaraActive comparatorEU sourced Stelara (ustekinumab)
Receives: Drug: Ustekinumab
US StelaraActive comparatorUS sourced Stelara (ustekinumab)
Receives: Drug: Ustekinumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. AUCinf

    Area under the concentration-time curve from time zero to infinity

    Measured: Day 1 to Day 99

  2. Cmax

    Maximum serum concentration

    Measured: Day 1 to Day 99

Secondary outcomes (3)

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Experience at least 1 TEAE

    Measured: Day 1 to Day 99

  2. Incidence of serious adverse events (SAEs)

    Experience at least 1 SAE

    Measured: Day 1 to Day 99

  3. Incidence of anti-drug antibodies (ADAs)

    Incidence of ADAs to ustekinumab

    Measured: Day 1 to Day 99

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Feb 2021
  2. Study start4 Feb 2021
  3. Primary completion1 Apr 2022
  4. Study completion1 Apr 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
201 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04772274
Sponsor's protocol ID
SB17-1001
Status last verified
Apr 2022
First submitted
23 Feb 2021
Last updated
5 Apr 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Ustekinumab in people with Healthy, run by Samsung Bioepis Co., Ltd. at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

AUCinf (time frame: Day 1 to Day 99). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04772274.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in